Related Experiment Videos
[The renin-angiotensin system in cardiovascular diseases]
C Unterberg1, H Kreuzer, A B Buchwald
1Abteilung Kardiologie und Pulmonologie der Medizinischen Universitätsklinik Göttingen.
Insights
The renin-angiotensin system plays a key role in heart failure. Blocking this system with ACE antagonists or angiotensin-receptor blockers improves hemodynamics and survival in heart failure patients.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Renal System
Context:
- The renin-angiotensin system (RAS) is implicated in cardiovascular diseases, particularly heart failure.
- It functions as both a circulating and a local system with distinct regulatory mechanisms.
- Interventions targeting the RAS, such as ACE inhibitors and angiotensin-receptor blockers, are established treatments for heart failure.
Purpose:
- To elucidate the mechanisms by which the renin-angiotensin system influences heart failure.
- To explain the therapeutic effects of RAS antagonists on cardiac and vascular remodeling.
- To highlight the interplay between the RAS, bradykinin, and endothelial function.
Summary:
- Heart failure activates the RAS as a compensatory response, leading to elevated angiotensin II and norepinephrine; antagonists acutely improve hemodynamics.
- Chronic RAS activation drives structural changes like myocardial hypertrophy and fibrosis, which are modulated by ACE antagonists and angiotensin-receptor blockers.
- The RAS interacts with the bradykinin system, influencing nitric oxide production and endothelial function, with further research needed on these complex relationships.
Impact:
- Provides a mechanistic understanding of RAS involvement in heart failure pathophysiology.
- Supports the continued use and development of RAS-targeting therapies for cardiovascular conditions.
- Suggests that further research into bradykinin system interactions could yield novel therapeutic strategies.
Background:
The renin-angiotensin system is mainly involved in several cardiovascular diseases and in the pathophysiology of heart failure. It exists as a circulating and a local system which can be differently regulated. Interventions in this system by angiotensin-converting enzyme (ACE) antagonists or angiotensin-receptor antagonists slow the progression of heart failure and result in prolongation of life expectancy and improvement of hemodynamics.
Mechanisms Of Action:
The main underlying mechanisms are: 1. Heart failure results in activation of the renin-angiotensin system as a compensatory mechanism with elevation of circulating angiotensin II, norepinephrine and vasopressin. Antagonists of this compensatory mechanisms acutely result in improvement of the hemodynamic situation. 2. Elevated circulating and local renin-angiotensin systems cause chronic structural myocardial and vascular effects. Angiotensin-converting enzyme antagonists and angiotensin-receptor blockers modulate and partly antagonize these structural changes such as myocardial hypertrophy, myocardial fibrosis and vascular proliferative responses. Gene and receptor regulation of the system are currently not fully understood and are subject of intensive research. 3. The renin-angiotensin system is closely related to the bradykinin system and thus indirectly to nitric oxide and endothelial function. Bradykinin has multiple other effects on the hemostatic system as a well as on the myocardium and vascular system.
Conclusion:
These complex interactions require further evaluation. Research with specific bradykinin antagonists will give new insights into this system.